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Combining multiple classes of antihypertensive drugs together is one
of the most important factors for achieving blood pressure control in
most hypertensive patients. The beneﬁts of combination therapy in
comparison with monotherapy include: a synergistic enhancement of
each drug’s hypertensive effects and a potential reduction of side
effects if each drug is used at a lower dose. Although long-acting
dihydropyridine calcium channel blockers and b-blockers are a good
ﬁt for combination therapy, because of the risk of atrioventricular block
and bradycardia, the combination of verapamil and b-blockers is not
advised. In addition, the combination of higher-dose diltiazem and
b-blockers is also not advised. b-blockers and diuretic agents as initial
lone combination therapy are not the preferred combination to be used
in uncomplicated hypertension. Using an angiotensin-converting
enzyme inhibitor as initial combination therapy with most b-blockers
is not recommended because of a lack of antihypertensive efﬁcacy.
Nebivolol, however, appears different in this regard and might provide
an opportunity for combining these 2 classes of agents with proven
cardiovascular beneﬁts for better blood pressure control. Adding an
a-blocker to a b-blocker is an effective combination.Received for publication August 16, 2013. Accepted August 26, 2013.
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ORESUME
La combinaison de multiples classes d’antihypertenseurs est l’un des
plus importants facteurs pour atteindre la regulation de la pression
arterielle chez la plupart des patients hypertendus. Les avantages d’un
traitement combine comparativement à la monotherapie incluent :
une amelioration de la synergie de chacun des effets hypertenseurs
des medicaments et une reduction potentielle des effets secondaires
si chaque medicament est utilise à plus faible dose. Bien que les
bloqueurs du canal calcique de la classe des dihydropyridines à action
prolongee et les b-bloquants conviennent au traitement combine, en
raison du risque de bloc auriculoventriculaire et de bradychardie, la
combinaison de verapamil et de b-bloquants n’est pas conseillee. De
plus, la combinaison de diltiazem à dose plus elevee et de b-bloquants
n’est egalement pas conseillee. Les b-bloquants et les diuretiques
comme seul traitement combine initial ne sont pas la combinaison à
privilegier lors d’hypertension non compliquee. L’utilisation d’un
inhibiteur de l’enzyme de conversion de l’angiotensine associe à la
plupart des b-bloquants comme multitherapie initiale n’est pas
recommandee en raison du manque d’efﬁcacite contre l’hypertension.
Cependant, le nebivolol semble different à cet egard et pourrait offrir la
possibilite de combiner ces 2 classes d’agents qui demontrent des
avantages cardiovasculaires conduisant à une meilleure regulation de
la pression arterielle. L’association d’un a-bloquant et d’un b-bloquant
est une combinaison efﬁcace.Combining multiple classes of antihypertensive drugs together
is one of the most important factors for achieving blood
pressure (BP) control in most hypertensive patients. Indi-
vidual drugs have unique proﬁles with differing sets of inter-
actions and side effects; therefore, knowledge in the use of safe
and effective drug combinations ensures that health care
providers are proﬁcient at managing hypertension. As an
example, two-thirds of the patients from the Hypertension
Optimal Treatment (HOT) trial with diastolic BPs of100 mm Hg or greater as an entry criteria required 2 or more
hypertensive agents to achieve optimal BP control.1 Similarly,
in the Antihypertensive Lipid-Lowering Treatment to Prevent
Heart Attack Trial (ALLHAT) study, the largest hypertension
study ever with more than 40,000 patients enrolled, more
than two-thirds of patients required 2 or more agents. Over
time, as the number of antihypertensive agents per person
increased, so did the fraction of patients achieving BP control.
After 5 years, BP control reached 80%.2 The beneﬁts of
combination therapy compared with monotherapy include:
a synergistic enhancement of each drug’s hypertensive effects
and a potential reduction of side effects if each drug is used at
a lower dose. The beneﬁts of achieving targets with combi-
nation therapy were demonstrated in an analysis of patients
after an acute coronary syndrome, in whom combining
therapies for risk factor reduction was associated with greatly
improved mortality.3 The 5 classes of medicationspen access under CC BY-NC-ND license.
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include angiotensin-converting enzyme (ACE) inhibitors,
angiotensin receptor blockers, b-blockers, calcium channel
blockers (CCBs), and diuretic agents. For each of these classes
there is sufﬁcient evidence, in people with hypertension,
demonstrating beneﬁt in hard outcomes such as a reduction of
mortality, stroke, or heart attack, to be included in the
Canadian Hypertension Education Program clinical practice
guidelines.4 In this article, the beneﬁts and cautions in
prescribing b-blockers in combination with other antihyper-
tensive agents with a focus on the most useful combinations
will be described (Table 1).b-Blockers and CCBs
Dihydropyridine CCBs
The 3 dihydropyridine (DHP) CCBs widely in use today
in Canada include: amlodipine, nifedipine, and felodipine.
Presently, the most commonly prescribed CCB is amlodipine;
it is available as a single generic drug and also in multiple
combinations, usually with an angiotensin receptor blocker.
These agents work by reducing peripheral vascular resistance
by blocking transmembrane movement of calcium, reducing
vascular smooth muscle tone. In the past, b-blockers have
been used in combination with short-acting CCBs to reduce
the tachycardia induced by these agents. With the develop-
ment of long-acting nifedipine and felodipine, the issue of
increased heart rate was markedly reduced; a faster heart rate
does not occur with the use of amlodipine.5 In addition to
improvements in heart rate, b-blockers and DHP CCBs
combine to produce reductions in BP that are greater than
when either agent is used alone. CCBs are metabolically
neutral, making them favourites for the initial management of
hypertension in severely hypertensive patients who have or areTable 1. Summary of beneﬁts and risks for b-blocker combination
therapy
Drug
Beneﬁts of combination
therapy
Risks/concerns of
combination therapy
Calcium channel
blockers
Dihydropyridine Additive blood pressure-
lowering effect
Improved heart rate
control
Nondihydropyridine Risk of bradycardia and
atrioventricular block
Diuretic agents Risk of negative
metabolic effects and
increased risk of
diabetes
ACEi and ARBs Third-generation
b-blockers might
produce an additive
blood pressure-
lowering effect
Lack of antihypertensive
efﬁcacy in
combination with
ﬁrst- and second-
generation b-blockers
a-Blockers Additive blood pressure-
lowering effect
Safe for use in patients
younger than the age
of 70 years
ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin
receptor blocker.at risk for metabolic complications. Even though CCBs have
a linear dose-response curve, there is much greater synergy for
BP control when adding another antihypertensive agent such
as a b-blocker to a CCB than is achieved by simply doubling
its dose.6
In summary, long-acting DHP CCBs and b-blockers are
a good ﬁt for combination therapy.
Non-DHP CCBs
Whereas DHP CCBs combine well with b-blockers, non-
DHP CCBs do not. Verapamil, in particular, but also dil-
tiazem at higher doses, should be avoided as concomitant
therapy with b-blockers, because of the risk of bradycardia and
atrioventricular block. A disproportionality analysis of adverse
events caused by drug interactions received by the US Food
and Drug Administration between the years 1968 and 2001
indicated that the rate of reporting b-blocker and verapamil
conduction-related interactions leading to bradycardias was
approximately 10%; double the rate reported for either agent
taken alone.7 Evidence for an interaction between b-blockers
and diltiazem comes from a 2009 study investigating the
reinfarction rates in non-Q-wave myocardial infarction
patients.8 Participants were randomly assigned to receive dil-
tiazem or placebo. Patients in the diltiazem arm received 360
mg of this agent daily for 14 days after a myocardial infarction
and 61% of the 287 patients in this group were already treated
with a b-blocker at baseline. In the placebo treatment arm,
64% of the 289 patients were taking a b-blocker at baseline.
At the end of the study, 3.4% of patients in the treatment
group developed a second-degree heart block compared with
0.5% of patients taking placebo.8
In summary, because of the risk of atrioventricular block
and bradycardia, the combination of verapamil and b-blockers
is not advised. In addition, the combination of higher-dose
diltiazem and b-blockers is also not advised.b-Blockers and Diuretic Agents
The use of b-blockers with diuretic agents was one of the
earliest forms of combined hypertension therapy and was used
widely in the 1980s. Earlier evidence for the efﬁcacy of
a stepped-care combination approach to therapy came from
the Hypertension Detection Follow-up Program (HDFP)9
and the Multiple Risk Factor Intervention Trial (MRFIT)10
which both combined diuretic agents with reserpine. In the
Medical Research Council Trial of Mild Hypertension
(MRC), b-blockers and diuretic agents were combined to treat
hypertension in older adults when a single agent failed to
produce a sufﬁcient change in BP.11 In this study, the diuretic
arm was found to be effective at preventing cardiovascular
outcomes whereas the b-blocker arm was not, possibly
because of earlier and greater BP control in the diuretic arm.
In the MRC trial, the b-blocker propranolol raised potassium
slightly and a thiazide diuretic reduced it slightly. Therefore,
initially the combination of b-blockers and diuretic agents
appeared advisable and was widely recommended for its
effectiveness at BP-lowering at a reasonable cost.
Further evidence for this combination came from the
Swedish Trial in Old Patients with Hypertension-2 (STOP-2)
study, designed to compare the cardiovascular and mortality
effects of conventional agents (b-blockers and diuretic agents)
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in the treatment of older patients with hypertension.12
Participants in the b-blocker arm were treated with atenolol,
metoprolol, or pindolol, and given hydrochlorothiazide and
amiloride as second-line treatment if needed to achieve BP
target. Patients in the CCB arm were treated with felodipine
or isradipine; second-line treatment was atenolol, metoprolol,
or pindolol. At the end of the study, 46.0% of all patients
were receiving combination therapy. There was no signiﬁcant
difference in BP control between the groups nor was there
a difference in frequency of fatal and nonfatal stroke or in
frequency of myocardial infarctions between the 2 treatment
groups. This is a reminder that diuretic agents and b-blockers
have demonstrated efﬁcacy in reducing mortality and reducing
cardiovascular morbidity.13 In the STOP-2 study there was
also no difference in new-onset diabetes between the 2
groups.12
Over time it was recognized that the combination of
b-blockers and diuretic agents did lead to metabolic changes,
in particular a predisposition to diabetes. The Systolic
Hypertension in the Elderly Program (SHEP) compared
chlorthalidone with placebo with the later addition of ateno-
lol. Initially a nonsigniﬁcant trend to more diabetes in the
treatment arm was noted (7.5% vs 6.4%).14 When the data
were reanalyzed using a fasting glucose of 7.0% as the deﬁ-
nition of diabetes, a signiﬁcant difference in diabetes rates
emerged. The treatment group experienced signiﬁcantly more
diabetes compared with the control group (13.0% vs 8.7%).
Further, results of a subanalysis were that signiﬁcantly more
patients taking chlorthalidone plus atenolol (16.4%) had
developed diabetes compared with those taking chlorthalidone
alone (11.8%).15 This indicates that adding atenolol to
diuretic agents increased the time-related trend to new dia-
betes. In a review, Mancia et al. concluded that diuretic agents
and b-blockers together might amplify the natural time-
dependent tendency toward the development of diabetes.16
In the Anglo-Scandinavian Cardiac Outcomes Trial
(ASCOT) - BP lowering arm, male and female hypertensive
patients were randomly assigned to treatment with
amlodipine-based combination therapy vs atenolol-based
combination therapy. Most patients in the ASCOT trial
received a second agent to reduce BP to target. In the amlo-
dipine arm, patients were treated with amlodipine and peri-
ndopril and the second agent in the atenolol group was
a thiazide diuretic. The study found signiﬁcantly fewer
cardiovascular events in patients with diabetes treated with
amlodipine/perindopril compared with b-blocker/diuretic
therapy.17 Metabolic markers including blood glucose, creat-
inine, and triglycerides were all signiﬁcantly higher, and high-
density lipoprotein cholesterol lower in patients treated with
b-blocker and diuretic-based therapy. There was a corre-
sponding increase in new-onset diabetes in the b-blocker/
diuretic treatment arm.18
In summary, b-blockers and diuretic agents as initial lone
combination therapy are not the preferred combination of
agents to be used in uncomplicated hypertension.b-Blockers and ACE Inhibitors
The ALLHAT study was designed to determine whether
treatment with ACE inhibitors and CCBs would lower theincidence of coronary heart disease and cardiovascular disease
compared with diuretic agents. A total of 33,357 hypertensive
patients 55 years of age and older and with at least 1 other
coronary heart disease risk factor were randomized to receive
treatment with lisinopril, amlodipine, or chlorthalidone,
excluding the doxazosin arm. Atenolol, reserpine, and cloni-
dine were added as second-line therapy to achieve BP reduc-
tion targets. Compared with patients in the chlorthalidone
group, patients randomized to the lisinopril group experienced
a 10% higher incidence of cardiovascular disease, 15% higher
incidence of stroke, and 19% higher incidence of heart failure.
Whereas atenolol and chlorthalidone combine to produce an
additive effect on lowering BP, the combination of lisinopril
and atenolol resulted in a 2 mm Hg higher systolic BP.
In a 2000 report, the Diabetes Executive Working Group
branch of the National Kidney Foundation reviewed a series
of randomized, prospective long-term studies that investigated
BP control in people with diabetes.19 The end points for this
review were cardiovascular events and progression of diabetic
nephropathy. The consensus from this report was to add
b-blockers to ACE inhibitors only in patients with heart rates
greater than 84 beats per minute because of a lack of efﬁcacy
in patients with lower heart rates.
In contrast to these ﬁndings, recent data using a smaller
population and a later generation b-blocker, suggest that there
might be additive effects between an ACE inhibitor and
nebivolol. In this study, combination therapy using nebivolol
and lisinopril was compared with monotherapy using each of
these agents separately, and placebo.20 The study involved 664
patients aged 18 to 64 with stage 2 diastolic hypertension. The
primary end point for this study was the change in diastolic BP
at the end of 6 weeks. The combination therapy group achieved
a response rate of 33.9% which was signiﬁcantly greater
compared with placebo (7.5%), nebivolol alone (21.6%), and
lisinopril alone (21.7%). The combination group experienced
a signiﬁcantly greater mean reduction in diastolic BP of 17.2
mm Hg vs 8.0 mm Hg in the placebo group, 13.3 mm Hg in
the nebivolol group, and 12.0 mm Hg in the lisinopril group.
Although this short-term study cannot be compared with the
ALLHAT study, the results suggest that third-generation b-
blocker agents might potentially provide a new combination
for the management of certain cases of hypertension.
In summary, using an ACE inhibitor as initial combination
therapy with most b-blockers is not recommended because of
a lack of antihypertensive efﬁcacy. There is however, some
data that suggest that nebivolol, unlike older-generation
b-blockers, might produce an additive effect in combination
with ACE inhibitors, but further study is required.b-Blockers and a-Blockers
a-Blockers work by blocking peripheral a receptors,
decreasing peripheral vascular resistance, and reducing BP.
a-Blockers were studied in the ALLHAT study in which 9061
patients received doxazosin as initial therapy for their hyper-
tension and were followed for a mean of 3.2 years.21 That
group was withdrawn early because of higher BP and an
increase in stroke and cardiovascular disease compared with
the diuretic arm, but there was no report of additional side
effects. These agents are therefore not recommended as ﬁrst-
line use in hypertension, but make sense when multiple
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tension. In the ALLHAT study, patients aged 55 and older
were studied and there were 591 patients age 80 and older.21
In the ASCOT trial, the a-blocker, doxazosin, was used as
a third-line therapy for patients when BP was not lowered to
140/90 with the use of 2 additional agents. The treatment
groups were amlodipine with perindopril as second-line
therapy and atenolol with bendroﬂumethiazide as second-
line therapy. Of the 19,257 participants in this trial
11,768 were treated with doxazosin at a median time point
of 8 months after randomization.22 The addition of dox-
azosin led to signiﬁcant reductions in systolic BP and dia-
stolic BP in all subgroups of this study. The addition of
doxazosin in the atenolol group led to a mean reduction in
systolic BP of 13.4 mm Hg vs a 9.4 mm Hg reduction in the
amlodipine group. Furthermore, the addition of doxazosin in
the atenolol group led to a 7.1 mm Hg diastolic BP reduc-
tion and in the amlodipine group, a 6.5 mm Hg diastolic BP
reduction.
In a 1990 double-blind, multicentre controlled trial, the
combination of doxazosin and atenolol was compared with
atenolol and placebo in patients with mild to moderate
hypertension.23 One hundred and thirteen patients aged
18-70 years were enrolled in this study, 87 of which
completed the double-blind portion of the study. At the end
of 12 weeks, patients in the combination group experienced
a signiﬁcant reduction in standing BP of 17.0/12.3 mm Hg in
contrast to the atenolol/placebo group which achieved
a reduction of 6.2/6.7 mm Hg. Patients in the combination
therapy group achieved a supine BP reduction of 13.2/9.8
mm Hg vs 9.2/6.0 mm Hg in the atenolol placebo group. The
difference in supine BP was not signiﬁcant.
In summary, adding an a-blocker to a b-blocker is an
effective combination in patients aged 70 years and younger.
b-Blockers have been used for many years to effectively
treat hypertension and reduce the incidence of cardiovascular
disease.24 b-Blockers combine well with DHP CCBs and
a-blockers. Although efﬁcacy is good with diuretic agents,
there is an increased risk of metabolic disturbance. There is
a risk of bradycardia and heart block with non-DHP CCBs
particularly with the use of verapamil. In combination with an
ACE inhibitor and by extension, angiotensin receptor blocker,
most b-blockers do not lead to synergy in BP-lowering,
however, there is a synergy in BP-lowering with the third-
generation b-blocker, nebivolol. b-Blockers as a class are
recommended in the Canadian Hypertension Education
Program clinical practice recommendations for use in
uncomplicated hypertension alone and in combination.
Having the knowledge of how to combine them with other
antihypertensive agents expands the armamentarium of the
clinician managing hypertension.Acknowledgements
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